Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
QuintilesIMS
Argus Health
Queensland Health
Cipla
Chinese Patent Office
Harvard Business School
Accenture
Medtronic
Cerilliant

Generated: October 19, 2017

DrugPatentWatch Database Preview

Valeant Pharms Llc Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT PHARMS LLC, and when can generic versions of VALEANT PHARMS LLC drugs launch?

VALEANT PHARMS LLC has seven approved drugs.

There are two US patents protecting VALEANT PHARMS LLC drugs.

There are three hundred and sixty-seven patent family members on VALEANT PHARMS LLC drugs in thirty-six countries and seventeen supplementary protection certificates in ten countries.

Summary for Applicant: Valeant Pharms Llc

International Patents:367
US Patents:2
Tradenames:6
Ingredients:6
NDAs:7
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms Llc
MESTINON
pyridostigmine bromide
TABLET;ORAL009829-002Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-001Jan 29, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
TIMOPTIC-XE
timolol maleate
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC020330-002Nov 4, 1993ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
TIMOPTIC-XE
timolol maleate
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC020330-001Nov 4, 1993ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
CAPITAL AND CODEINE
acetaminophen; codeine phosphate
SUSPENSION;ORAL086024-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-002Jan 29, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Pharms Llc
MESTINON
pyridostigmine bromide
TABLET, EXTENDED RELEASE;ORAL011665-001Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
LIBRIUM
chlordiazepoxide hydrochloride
INJECTABLE;INJECTION012301-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Valeant Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms Llc
TIMOPTIC-XE
timolol maleate
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC020330-002Nov 4, 1993► Subscribe► Subscribe
Valeant Pharms Llc
LIBRIUM
chlordiazepoxide hydrochloride
INJECTABLE;INJECTION012301-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-002Jan 29, 1998► Subscribe► Subscribe
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-001Jan 29, 1998► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
TASMAR
tolcapone
TABLET;ORAL020697-002Jan 29, 1998► Subscribe► Subscribe
Valeant Pharms Llc
TIMOPTIC-XE
timolol maleate
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC020330-001Nov 4, 1993► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
TIMOPTIC-XE
timolol maleate
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC020330-002Nov 4, 1993► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Valeant Pharms Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,964,572High affinity nucleic acid ligands of complement system proteins► Subscribe
5,789,157 Systematic evolution of ligands by exponential enrichment: tissue selex► Subscribe
5,654,151 High affinity HIV Nucleocapsid nucleic acid ligands► Subscribe
5,958,691 High affinity nucleic acid ligands containing modified nucleotides► Subscribe
5,773,598 Systematic evolution of ligands by exponential enrichment: chimeric selex► Subscribe
5,270,163 Methods for identifying nucleic acid ligands► Subscribe
6,395,888 High affinity nucleic acid ligands of complement system proteins► Subscribe
5,874,218 Method for detecting a target compound in a substance using a nucleic acid ligand► Subscribe
7,094,535Nucleic acid ligands to integrins► Subscribe
6,028,186 High affinity nucleic acid ligands of cytokines► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Valeant Pharms Llc Drugs

Country Document Number Estimated Expiration
Germany60042021► Subscribe
Japan4335975► Subscribe
Austria494394► Subscribe
Spain2349213► Subscribe
Denmark1042348► Subscribe
Australia2004242462► Subscribe
European Patent Office0840739► Subscribe
Japan2003506024► Subscribe
Austria470712► Subscribe
World Intellectual Property Organization (WIPO)9640703► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Valeant Pharms Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2006004Lithuania► SubscribePRODUCT NAME: PEGAPTANIBUM; REG. NO/DATE: EU/1/05/325/001 20060131
C0013Belgium► SubscribePRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
C024/2006Ireland► SubscribeSPC024/2006:, EXPIRES: 20210130
/1997Austria► SubscribePRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 - EU/1/97/044/006 19970827
C/GB99/043United Kingdom► SubscribePRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
2006 00021Denmark► Subscribe
0234Netherlands► Subscribe300234, 20171017, EXPIRES: 20210130
C/GB97/088United Kingdom► SubscribePRODUCT NAME: TOLCAPONE; REGISTERED: CH 54055/01 19970225; CH 54055/02 19970225; UK EU/1/97/044/001 19970827; UK EU/1/97/044/002 19970827; UK EU/1/97/044/003 19970827; UK EU/1/97/044/004 19970827; UK EU/1/97/044/005 19970827; UK EU/1/97/044/006 19970827
00C/001Belgium► SubscribePRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
2006004,C0957929Lithuania► SubscribePRODUCT NAME: PEGAPTANIBUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Harvard Business School
US Army
Novartis
Boehringer Ingelheim
Baxter
US Department of Justice
Colorcon
Argus Health
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot